Disparities in Breast Cancer Outcomes for Black Women Despite Similar Recurrence Scores
Black breast cancer patients had worse outcomes in a recent study, even when cancer features aligned with white patients.
Progress Against Cancer
Black breast cancer patients had worse outcomes in a recent study, even when cancer features aligned with white patients.
Medical marijuana used as a substitute for opioids, and chemo and endocrine therapy together increase cancer-related cognitive impairment.
The FDA approved the PD-L1 inhibitor atezolizumab to treat alveolar soft part sarcoma The U.S. Food and Drug Administration has approved atezolizumab (Tecentriq) for the treatment of patients 2 years of age or older...
AACR patient advocate forum explores how new clinical trial designs are accelerating drug testing.
Oncologists report that prior authorization interrupts cancer care, plant-based diet is associated with lower colorectal cancer risk in men, and more from this week in cancer news.
A second inhibitor of mutant IDH1 was approved to treat certain blood cancers. The U.S. Food and Drug Administration (FDA) has approved olutasidenib (Rezlidhia) for patients with relapsed or refractory acute myeloid leukemia (AML)...
While some people realize that drinking increases the risk of cancer, a few think it actually lowers the risk, a study finds. Many Americans are unaware of the fact that consuming alcoholic beverages of...
California passes ballot initiative banning flavored tobacco products, and the FDA approves combination treatments for lung cancer.
A targeted therapy was approved for a subset of treatment-resistant ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment...
The FDA approved the immune checkpoint inhibitor tremelimumab to treat certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved the immunotherapeutic tremelimumab (Imjudo) in combination with the...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More